Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L.
Int J Mol Sci. 2017;18(4). pii: E837. doi: 10.3390/ijms18040837.

Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in Myelodysplastic Syndromes and Permits a Better Definition of the Intermediate Risk Category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ana F, Sanz GF, Florensa L; Grupo Español de Síndromes Mielodisplásicos (GESMD)
Am J Hematol. 2017;92(7):614-621.

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.
Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J.
Oncotarget. 2017;8(63):106948-106961. doi: 10.18632/oncotarget.22157.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.
de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenková D, Vallespí T, Zini G, Paszkowska-Kowalewska M, Kruger A, Saft L, Fenaux P, Bowen D, Hellström-Lindberg E, ?ermák J, Stauder R, Tatic A, Holm MS, Malcovati L, M?dry K, Droste J, Blijlevens N, de Witte T, Germing U.
Ann Hematol. 2017;96(7):1105-1112.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.
Blood. 2017;129(13):1753-1762.

Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.
Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR.
Leuk Res. 2017;52:1-7.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.
J Hematol Oncol. 2017;10(1):131.

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ? 30% blasts.
Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG.
Leukemia. 2017;31(12):2799-2806.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.
Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W.
Biol Blood Marrow Transplant. 2017;23(6):971-979.

Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload.
Ivars D, Orero MT, Javier K, Díaz-Vico L, García-Giménez JL, Mena S, Tormos C, Egea M, Pérez PL, Arrizabalaga B, Ruiz MÁ, Yagüe N, Tormo M, Sancho-Tello R, Gomes A, Algueró C, O’Connor JE, Sáez GT, Carbonell F, Collado R.
Clin Biochem. 2017;50(16-17):911-917.

A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
Janusz K, Del Rey M, Abáigar M, Collado R, Ivars D, Hernández-Sánchez M,Valiente A, Robledo C, Benito R, Díez-Campelo M, Ramos F, Kohlmann A, Cañizo CD, Hernández-Rivas JM.
Leuk Res. 2017;56:82-7.

Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis.
Montoro J, Robledo C, Zamora L, Valcárcel D, Ramos F.
Ann Hematol. 2017;96(2):317-8.

Excess mortality in the myelodysplastic syndromes.
Nomdedeu M, Pereira A, Ramos F, Valcárcel D, Costa D, Arnan M, Calvo X, Pomares H, Luño E, Díaz-Campelo M, Collado R, de Paz R, Falantes JF, Pedro C, Marco J, Oirtzabal I, Sánchez-García J, Tormo M, Cedena MT, Nomdedeu B, Sanz G; Spanish MDS Group.
Am J Hematol. 2017;92(2):149-54.

Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.
Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, Gomez C, Luño E, Cervera J, Arnan M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernandez-Rivas JM, Díez-Campelo M, Ortega M,Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group.
Leuk Res. 2017;63:85-89.

Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect.
Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D.
Exp Hematol. 2017;48:1-11.

Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia.
Palau A, Mallo M, Palomo L, Rodríguez-Hernández I, Diesch J, Campos D, Granada I, Juncà J, Drexler HG, Solé F, Buschbeck M.
Genes Chromosomes Cancer. 2017;56(3):243-252.

Inspecting targeted deep sequencing of whole genome amplified DNA versus fresh DNA for somatic mutation detection: A genetic study in myelodysplastic syndrome patients.
Palomo L, Fuster-Tormo F, Alvira D, Ademà V, Armengol MP, Gómez-Marzo P, Haro N, Mallo M, Xicoy B, Zamora L, Solé F.
Biopreserv Biobank. 2017;15(4):360-365.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.
J Clin Oncol. 2017;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271.

Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.
Paviglianiti A, Ruggeri A, Volt F, Sanz G, Milpied N, Furst S, Esquirol A, Arcese W, Picardi A, Ferra C, Ifrah N, Bourhis JH, Raj K, von dem Borne PA, Sica S, Menard AL, Bloor A, Kenzey C, Gluckman E, Rocha V.
Br J Haematol. 2017;179(5):790-801.

Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study.
Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luño E, Caballero M, Solano F, Almagro M, Xicoy B, Jiménez M.
Eur J Cancer Care (Engl). 2017;26(6). doi: 10.1111/ecc.12426.

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.
Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, María Hernández-Rivas J; Spanish Group for Myelodysplastic Syndromes (GESMD).
Am J Hematol. 2017;92(9):E534-E541.